SHANGHAI–(BUSINESS WIRE)–Shanghai Immunocan Biotech Co., Ltd. (“Immunocan”) today announced the successful in situ replacement of megabase (Mb)-scale human immunoglobulin (Ig) gene segments at endogenous Ig loci in rabbits using its proprietary MASIRT® (Massive-fragment Across Species In situ Replacement Technology) platform. Genotypic characterization confirmed targeted, single-step replacement with the human sequences. Unlike conventional transgenic approaches that often rely on random inte